3 Reasons to Buy Pfizer Stock Now
After years of underperformance, the future is looking brighter for the drugmaker.
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October
You don't need to be rich to put your money to work on Wall Street.
3 Things You Need to Know if You Buy Pfizer Today
Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
These stocks could see growth take off over the next few years.
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial - Metsera ( NASDAQ:MTSR )
Metsera, Inc. ( NASDAQ:MTSR ) on Tuesday released topline data from VESPER-1 and data from a planned interim analysis for tolerability of VESPER-3 - two Phase 2b trials of MET-097i with potential for monthly dosing.
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out
The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PINC, MTSR, HOUS, ODP on Behalf of Shareholders - Metsera ( NASDAQ:MTSR ) , Anywhere Real Estate ( NYSE:HOUS )
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Right now, these dividend payers are top options for folks who like to set it and forget it.
Down 55%, Should You Buy the Dip on Pfizer?
Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track.
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
The company continues to improve its pipeline.
3 Magnificent Stocks Under $100 to Buy Right Now
You won't need a huge amount of cash to invest in these great pharma stocks.
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - MTSR, HOUS, PINC, and FNBT
NEW YORK, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?
The pharmaceutical giant is again plunging headfirst into weight-loss drug development.
2 Top Passive Income Stocks to Buy Now
These dividend stocks offer high yields and growth catalysts that could support payouts for decades.
3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now
These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.
Pfizer's Metsera acquisition to spur Chinese search for new weight drugs
American pharmaceutical giant Pfizer's up to US$7.3 billion acquisition of next-generation weight loss drugs developer Metsera will encourage more research spending on innovative products in China but is unlikely to draw new players into the fray, according to analysts.
Does This Acquisition Make Pfizer Stock a Great Buy?
There's an opportunity to get in on the weight-loss drug craze at a reasonable price.
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
3 Top Dividend Stocks to Buy and Hold Forever
These blue chip dividend stocks offer both income and growth potential.
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.
Investors once speculated that Pfizer might consider acquiring Viking.
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
Time to Buy Pfizer ( PFE ) or Metsera ( MTSR ) Stock?
Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, GTLS, MURA on Behalf of Shareholders - Aris Water Solutions ( NYSE:ARIS ) , Chart Industries ( NYSE:GTLS )
NEW YORK, Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aris Water Solutions, Inc.
Can PFE Successfully Return to the Obesity Space With Metsera Buyout?
Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, ODP, SMLR on Behalf of Shareholders - Metsera ( NASDAQ:MTSR ) , Aris Water Solutions ( NYSE:ARIS )
NEW YORK, Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aris Water Solutions, Inc.
Company News for Sep 23, 2025
Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.
What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?
Pfizer's plan to enter the booming obesity market took an expensive new turn.
Why Pfizer Stock Just Popped
Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. ( Nasdaq - PINC ) , Metsera, Inc. ( Nasdaq - MTSR ) , Anywhere Real Estate Inc. ( NYSE - HOUS ) , The ODP Corporation ( Nasdaq - ODP )
BALA CYNWYD, Pa., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera - Pfizer ( NYSE:PFE )
SAN DIEGO, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. MTSR breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. PFE.
Gold Gains Over 1%; Quantum Computing Shares Plunge - AgriFORCE Growing Systems ( NASDAQ:AGRI ) , Chijet Motor Co ( NASDAQ:CJET )
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded up 0.01% to 46,321.12 while the NASDAQ rose 0.24% to 22,685.77. The S&P 500 also rose, gaining, 0.15% to 6,674.60. Information technology shares jumped by 0.4% on ...
PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Monday - Diginex ( NASDAQ:DGNX ) , Banco BBVA Argentina ( NYSE:BBAR )
U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Monday. Shares of PROS Holdings, Inc. PRO rose sharply during Monday's session after the company announced it will be acquired by Thoma Bravo. PROS Holdings shares jumped 40% to $22.97 on Monday.
Pfizer Buys Matsera For $5 Billion, Boosts Obesity Portfolio - Metsera ( NASDAQ:MTSR ) , Pfizer ( NYSE:PFE )
Pfizer Inc. PFE on Monday agreed to acquire Metsera, Inc. MTSR to accelerate the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings a portfolio of differentiated oral and injectable incretin, non-incretin, and combination therapy candidates.
Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
Metsera, founded in 2022, brings a pipeline of both oral and injectable treatments with different targets that could boost Pfizer's odds of entering the market.
Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market - Invesco International Growth Focus ETF ( BATS:MTRA ) , Eli Lilly ( NYSE:LLY )
Pfizer Inc. PFE stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. MTSR, a developer of anti-obesity drugs.
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting - Metsera ( NASDAQ:MTSR )
NEW YORK, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Metsera, Inc.
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
NEW YORK, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Metsera, Inc. ( Nasdaq: MTSR ) , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will present clinical and preclinical data from its portfolio of next-generation ultra-long ...
Recent Price Trend in Metsera Inc. ( MTSR ) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Metsera Inc. (MTSR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - ATAI Life Sciences ( NASDAQ:ATAI ) , Cantor Equity Partners I ( NASDAQ:CEPO )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday. Shares of ATAI Life Sciences NV ATAI fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with ...
Wall Street Analysts See a 55.72% Upside in Metsera Inc. ( MTSR ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Metsera Inc. (MTSR) points to a 55.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - BitMine Immersion Techs ( AMEX:BMNR ) , Altimmune ( NASDAQ:ALT )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday. Shares of Methode Electronics, Inc. MEI fell sharply in today's pre-market trading after the company reported a fourth-quarter adjusted EPS miss.
Nasdaq Welcomes 142 IPOs in the First Half of 2025
Highest volume of listings and capital raise in the first half of the year since ...
Nasdaq Welcomes 142 IPOs in the First Half of 2025
Nasdaq Welcomes 142 IPOs in the First Half of ...
Nasdaq Welcomes 142 IPOs in the First Half of 2025 - Nasdaq ( NASDAQ:NDAQ )
Highest volume of listings and capital raise in the first half of the year since 2021 Maintained leadership in switches - crossed $3 trillion in market value transferred since 2005 Driving smart policy reforms to improve regulatory processes for public companies
Wall Street Analysts See an 89.66% Upside in Metsera Inc. ( MTSR ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday - AST SpaceMobile ( NASDAQ:ASTS ) , Couchbase ( NASDAQ:BASE )
U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Friday. Shares of The Kroger Co. KR rose sharply during Friday's session after the company reported better-than-expected first-quarter adjusted EPS results.
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference - Metsera ( NASDAQ:MTSR )
NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Metsera, Inc.
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Metsera, Inc. ( Nasdaq: MTSR ) ( "Metsera" or the "Company" ) , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive ...
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data - Metsera ( NASDAQ:MTSR )
MET-233i shows 8.4% mean placebo-subtracted weight loss after five weekly 1.2 mg doses. MET-233i's 19-day half-life supports monthly dosing with favorable tolerability and no serious safety signals. Get access to the leaderboards pointing to tomorrow's biggest stock movers. Metsera, Inc.
